Cellectar Biosciences (CLRB) announces the appointment of William Yoon, PharmD, MBA/HCM as vice president, VP, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom’s macroglobulinemia in Q4 2023. Prior to joining Cellectar Biosciences, Yoon held the position of Head of Clinical and Value Evidence at Immunogen (IMGN). Nanduri brings a wealth of experience in data and operations, acquired through key roles at organizations such as BeiGene (BGNE), Celgene Corporation, and Ernst & Young.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLRB:
- Cellectar Biosciences files to sell 34.49M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
- Cellectar Biosciences secures four patents across key global regions
- Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia